(NASDAQ: ACON) Aclarion Inc.  moving up more than 40% at lunch time on recently announced news of closing of public offering and trading on NASDAQ Capital markets.

SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. (“Aclarion” or the “Company”) (NASDAQ:ACON) (NASDAQ:ACONW), ahealthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the closing of its previously announced initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock with an exercise price of $4.35 per share at a combined offering price of $4.35, for gross proceeds of approximately $9.4 million, before deducting underwriting discounts and offering expenses. In addition, Aclarion has granted the underwriters a 45-day option to purchase up to an additional 324,750 shares of common stock and/or warrants to purchase 324,750 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount, of which Maxim Group LLC has exercised its option to purchase an additional 324,750 warrants.

The shares of common stock and warrants began trading on The Nasdaq Capital Market on April 22, 2022, under the symbols “ACON” and “ACONW,” respectively.

Maxim Group LLC acted as the sole book-running manager in connection with the offering.

A registration statement on Form S-1 (File No. 333-262026) was filed with the Securities and Exchange Commission (“SEC”), which became effective on April 21, 2022. A final prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at. The offering was made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, at (212) 895-3745. Before investing in this offering, interested parties should read in its entirety the registration statement that the Company has filed with the SEC, which provides additional information about the Company and this offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.